179 related articles for article (PubMed ID: 19787091)
1. Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.
Hayashi T; Shimamura Y; Saegusa T; Horiuchi A; Kobayashi Y; Hiraoka N; Kanai Y; Aburatani H; Sano K; Konishi I
Gene Regul Syst Bio; 2008 Jul; 2():297-305. PubMed ID: 19787091
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.
Hayashi T; Kawano M; Ichimura T; Ida K; Ando H; Zharhary D; Kanai Y; Aburatani H; Tonegawa S; Shiozawa T; Yaegashi N; Konishi I
Anticancer Res; 2016 Oct; 36(10):4997-5007. PubMed ID: 27798858
[TBL] [Abstract][Full Text] [Related]
3. Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1.
Hayashi T; Horiuchi A; Sano K; Yaegashi N; Konishi I
Anticancer Res; 2015 Sep; 35(9):4665-79. PubMed ID: 26254356
[TBL] [Abstract][Full Text] [Related]
4. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Tagawa Y; Nishimura R; Ishiko O; Kanai Y; Yaegashi N; Aburatani H; Shiozawa T; Konishi I
Sci Rep; 2011; 1():180. PubMed ID: 22355695
[TBL] [Abstract][Full Text] [Related]
5. Uterine leiomyosarcoma: present management.
Giuntoli RL; Bristow RE
Curr Opin Oncol; 2004 Jul; 16(4):324-7. PubMed ID: 15187886
[TBL] [Abstract][Full Text] [Related]
6. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912
[TBL] [Abstract][Full Text] [Related]
7. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
Hayashi T; Kobayashi Y; Kohsaka S; Sano K
Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
[TBL] [Abstract][Full Text] [Related]
8. Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
Sarcoma; 2011; 2011():476498. PubMed ID: 21437229
[TBL] [Abstract][Full Text] [Related]
9. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
10. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
11. Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Nagase S; Ishiko O; Shiozawa T; Kanai Y; Yaegashi N; Aburatani H; Tonegawa S; Konishi I
N Am J Med Sci; 2011 Sep; 3(9):394-9. PubMed ID: 22362447
[TBL] [Abstract][Full Text] [Related]
12. Potential role of LMP2 as an anti-oncogenic factor in human uterine leiomyosarcoma: morphological significance of calponin h1.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Nishimura R; Ishiko O; Shiozawa T; Kanai Y; Yaegashi N; Aburatani H; Konishi I
FEBS Lett; 2012 Jun; 586(13):1824-31. PubMed ID: 22659265
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Leiomyosarcoma: Induction of Hematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells.
Hayashi T; Sano K; Ichimura T; Kanai Y; Zharhary D; Aburatani H; Yaegashi N; Konishi I
Anticancer Res; 2020 Mar; 40(3):1255-1265. PubMed ID: 32132022
[TBL] [Abstract][Full Text] [Related]
14. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract][Full Text] [Related]
15. Preoperative diagnosis of usual leiomyoma, atypical leiomyoma, and leiomyosarcoma.
Matsuda M; Ichimura T; Kasai M; Murakami M; Kawamura N; Hayashi T; Sumi T
Sarcoma; 2014; 2014():498682. PubMed ID: 25400500
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
17. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.
Hayashi T; Faustman DL
Cancer Res; 2002 Jan; 62(1):24-7. PubMed ID: 11782352
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
19. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
20. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
Sibille C; Gould KG; Willard-Gallo K; Thomson S; Rivett AJ; Powis S; Butcher GW; De Baetselier P
Curr Biol; 1995 Aug; 5(8):923-30. PubMed ID: 7583150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
